RECRUITING

Novel Tracer Methods to Evaluate Muscle Protein Metabolism in Cirrhosis

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To determine the rate and mechanisms of skeletal muscle protein synthesis and breakdown in cirrhotic patients by using multiple tracers and single muscle biopsies.

Official Title

Multiple Tracer Using Single Muscle Biopsy Technique in Evaluating Protein Synthesis and Break Down in Muscles of Cirrhotic Patients

Quick Facts

Study Start:2017-08-03

Study Completion:2025-09-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03225677

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Not specified

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* The diagnosis of cirrhosis based on liver biopsy and/or clinical, biochemical, and imaging criteria. * Patients with Child Pugh score from A5- to B7 * Control group: Subject in control group should have serum ALT and AST within normal range. * diabetes * cancer * kidney failure * pregnancy * recent surgery (bowel resection or Gastric bypass operation) * Advanced cardiac or pulmonary disease * patient with thyroid disease \& Coagulopathy ( INR \>1.4 and platelet count \<80,000/ml)	Pregnancy or breastfeeding Severe psychiatric disorders Active substance abuse Unstable medical conditions Inability to comply with study requirements

Inclusion Criteria

Exclusion Criteria

* The diagnosis of cirrhosis based on liver biopsy and/or clinical, biochemical, and imaging criteria.
* Patients with Child Pugh score from A5- to B7
* Control group: Subject in control group should have serum ALT and AST within normal range.
* diabetes
* cancer
* kidney failure
* pregnancy
* recent surgery (bowel resection or Gastric bypass operation)
* Advanced cardiac or pulmonary disease
* patient with thyroid disease \& Coagulopathy ( INR \>1.4 and platelet count \<80,000/ml)

Pregnancy or breastfeeding
Severe psychiatric disorders
Active substance abuse
Unstable medical conditions
Inability to comply with study requirements

Contacts and Locations

Study Contact

Annette Bellar, MSLA

CONTACT

2164450688

bellara@ccf.org

Principal Investigator

Srinivasan Dasarathy, MD

PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Study Locations (Sites)

Cleveland Clinic Foundation

Cleveland, Ohio, 44195

United States

Collaborators and Investigators

Sponsor: The Cleveland Clinic

Srinivasan Dasarathy, MD, PRINCIPAL_INVESTIGATOR, The Cleveland Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-08-03

Study Completion Date2025-09-30

Study Record Updates

Study Start Date2017-08-03

Study Completion Date2025-09-30

Terms related to this study

Additional Relevant MeSH Terms

Cirrhosis